DALLAS - Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a biotechnology firm specializing in gene therapies for central nervous system diseases, has made significant strides in its pipeline restructuring efforts. The company announced today that it has progressed with several previously deprioritized programs by transferring rights and initiating collaborations, ensuring the continuation of their development.
The company has successfully transferred the Investigational New Drug (IND) application and clinical trial materials for TSHA-120, aimed at treating giant axonal neuropathy (GAN), to the National Institute of Neurological Disorders and Stroke (NINDS). Discussions are also underway to transfer rights for TSHA-120 back to the originating advocacy organization.
In a move to focus on their lead program TSHA-102 for Rett syndrome, Taysha has returned exclusive intellectual property rights for TSHA-101, targeting GM2 gangliosidosis, to Queen’s University. Rights for other programs, such as TSHA-104 for SURF1-associated Leigh syndrome and TSHA-112 for APBD, have been transferred back to the originating institutions.
Additionally, Taysha has provided clinical trial material for TSHA-118 in CLN1 to RUSH University Medical Center to support an individual-patient IND request for a patient with CLN1 disease.
These developments follow a management change in December 2022 and are facilitated by a new loan and security agreement from November 13, 2023, which allows the company to transfer IP rights efficiently and extends its cash runway into 2026. This strategic move aims to place these gene therapy programs into the hands of entities that can further their development, potentially benefiting patients with these rare diseases.
Sean P. Nolan, Chairman and CEO of Taysha, expressed satisfaction in ensuring that the right advocates, clinicians, and scientific experts can advance these programs. The company continues to seek partnerships and opportunities for its other deprioritized programs.
Taysha Gene Therapies remains committed to advancing its lead clinical program TSHA-102 and to addressing the unmet medical needs of patients with severe monogenic CNS diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.